Plexāā is a pioneering UK MedTech company focused on improving surgical outcomes through innovative solutions.

Their flagship device, BLOOM⁴³ enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect 1 in 3 women undergoing breast surgery.

BLOOM⁴³ is the world’s first fully wearable, non-invasive and FDA- approved medical device that allows patients to safely precondition their skin the night before surgery.

By gently warming the area, the body release Heat Shock Proteins (HSPs). These naturally occurring proteins cause the release of carbon monoxide into the tissue which vasodilates the blood vessels and improves the blood flow to the skin.

This improved blood flow primes the skin to heal and has been shown to prevent wound healing complications in proof-of-concept clinical trials.

Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes.